StemCell Therapy

Stem cells are powerful, adaptable cells that can be used to promote healing and reverse damage. Stem cells are found in various places within the human body, but the purest stem cells are found in the umbilical cord.

Stem cells can be used in treatments for many different types of diseases. One of the main places young stem cells are found is in cord blood, which can be stored at birth and saved for future use if needed. Stem cells are also found in other places in the human body, including blood and bone marrow.

Regenerative transplants use stem cells from three main sources:

Bone marrow is tissue located in the center of your bones, making healthy blood cells that strengthen your immune system and fight off outside infections. A large amount of cells are located in bone marrow, and doctors frequently use hip bone marrow for most transplants, since the stem cells in this area are the most plentiful.

When doctors remove bone marrow, the patient receives anesthesia. This puts them to sleep and numbs any pain from the surgery. Doctors then insert a large needle, and pull the liquid marrow out. Once enough bone marrow is harvested, the solution is filtered and cryogenically frozen.

When a patient needs bone marrow for a transplant, stem cells are thawed and injected into the bloodstream. The cells then make their way to the bone marrow, and start producing new blood cells this process usually takes a few weeks.

While most people have a small amount of stem cells in their bloodstream, donors produce more stem cells after taking growth factor hormones. Doctors give these medications a few days before stem cell harvesting, which makes the bone marrow push more cells into the bloodstream.

During the harvesting procedure, doctors use a catheter to draw out blood. The blood moves through a machine, which separates stem cells and allows these cells to be put into storage. This process takes a few hours, and may be repeated over several days in order for doctors to get enough stem cells.

Stem cells are injected into the veins during a peripheral blood transplant, and naturally work their way to the bone marrow. Once there, the new cells start increasing healthy blood count. Compared to bone marrow transplants, cells from peripheral blood are usually faster, creating new blood cells within two weeks.

Umbilical cord blood contains a large amount of stem cells. If parents sign up for personalized storage or donation, medical staff will remove stem cells from the umbilical cord and placenta. The blood is then cryogenically frozen, and put into long-term storage.

While the stem cell count is smaller during a cord blood transplant, these cells multiply quickly, and researchers are studying new methods to increase cells naturally. Compared to bone marrow, cord blood cells multiply faster and dont require an exact match type to complete a successful transplant. Some techniques medical experts are testing to increase the amount of stem cells include:

While all three stem cell sources are used in similar procedures, they each have advantages and drawbacks. Bone marrow transplants are the traditional form of therapy, but peripheral blood cells are becoming more popular, since doctors often get more stem cells from the bloodstream.

The procedure for peripheral blood harvesting is easier on the patient than a bone marrow transplant, and stem cell transplants are faster. However, the chances for graft-versus-host disease, where donated cells attack the patients body, are much higher after a peripheral blood transplant.

Cord blood transplants are the least invasive, since they come from an external source the umbilical cord.

The biggest advantage for cord blood is the immaturity of the cells, which means transplants do not require an exact match. For bone marrow and peripheral blood transplants, donors need to match the patients cellular structure. However, cord blood cells can adapt to a wide variety of patients, and dont require donor matching. Chances for graft-versus-host disease are also much lower for cord blood transplants.

Patients and doctors can avoid graft-versus-host disease, and other dangerous side effects, by using HLA matching.

Multipotent stem cells develop into organ system cells, and are made from two different types of cells:

HSCs can become any type of blood cell or cellular blood component inside the body, including white blood cells and red blood cells. These cells are found in umbilical cord blood and are multipotent, which means they can develop into more than one cell type.

This cell type has been used in over 1 million patient transplants around the world.

MSCs can turn into bone, cartilage, fat tissue, and more. Although they are associated with bone marrow, these cells are also found in umbilical cord blood. These cells can function as connective tissue, which connects vital organs inside the body. Like HSCs, MSCs are multipotent.

Pluripotent cells can replace any type of cellular system in the body. Cord blood contains a rich variety of pluripotent stem cells, which allows treatment for a large amount of patients.

iPS cells are artificially-made pluripotent stem cells. This technique allows medical staff to create additional pluripotent cells, which will increase treatment options for patients using stem cell therapy in the near future.

ES cells are pluripotent, and similar to iPS cells, but come from an embryo. However, this kills the fertilized baby inside the embryo. This type of cell also has a high chance for graft-versus-host disease, when transplanted cells attack the patients body.

Your adult cells have one disadvantage to cord blood cells they cannot change their cell type. When stem cells from cord blood and tissue are transplanted, they adjust to fit the individual patient and replace damaged cells. Adult stem cells are also older, which means they have been exposed to disease, and may damage patients after the transplant. Compared to cord blood cells, adult cells have a higher chance for graft-versus-host disease.

Cord blood contains a wide variety of cell types, but there are different stem cell sources available to patients in need of a transplant.

Last Updated on February 15th, 2017

Original post:
Stem Cells Used in Cord Blood Treatments

One of the bravest moves in that direction has come from stem cell research and therapy. Stem cell therapy is currently being used to successfully treat more than 80 diseases, but the field is rapidly evolving backed by prestigious research and clinical trials.

Smart Cells is the first private UK stem cell storage company to have released stored stem cell units for use in the treatment of children with life-threatening illnesses. We have released the greatest number of samples for use in transplants from the UK.

We believe with the development of technology in the future we will be able to treat even more illnesses.

We believe our customers deserve the best service available and we run our state of the art facility with leading professionals in the field.

We believe that storing your childs stem cells at birth can be a crucial part of treating or curing an unexpected illness.

We believe that in the future this service should be available to every parent, child and family.

We are a company that is for life.

View post:
Storing Stem Cells For Life - Smart Cells

- 183 records -

Original Research

Galvez JM, Restrepo CM, Contreras NC, Alvarado C, Caldern-Ospina CA, Pea N, Cifuentes RA, Duarte D, Laissue P, Fonseca DJ

Pharmacogenomics and Personalized Medicine 2018, 11:169-178

Published Date: 16 October 2018

Sychev DA, Levanov AN, Shelekhova TV, Bochkov PO, Denisenko NP, Ryzhikova KA, Mirzaev KB, Grishina EA, Gavrilov MA, Ramenskaya GV, Kozlov AV, Bogoslovsky T

Pharmacogenomics and Personalized Medicine 2018, 11:167-168

Published Date: 26 September 2018

Sychev DA, Levanov AN, Shelekhova TV, Bochkov PO, Denisenko NP, Ryzhikova KA, Mirzaev KB, Grishina EA, Gavrilov MA, Ramenskaya GV, Kozlov AV, Bogoslovsky T

Pharmacogenomics and Personalized Medicine 2018, 11:127-137

Published Date: 25 July 2018

Hernandez-Suarez DF, Botton MR, Scott SA, Tomey MI, Garcia MJ, Wiley J, Villablanca PA, Melin K, Lopez-Candales A, Renta JY, Duconge J

Pharmacogenomics and Personalized Medicine 2018, 11:95-106

Published Date: 8 June 2018

Kryukov AV, Sychev DA, Andreev DA, Ryzhikova KA, Grishina EA, Ryabova AV, Loskutnikov MA, Smirnov VV, Konova OD, Matsneva IA, Bochkov PO

Pharmacogenomics and Personalized Medicine 2018, 11:43-49

Published Date: 22 March 2018

Original Research

St Sauver JL, Olson JE, Roger VL, Nicholson WT, Black III JL, Takahashi PY, Caraballo PJ, Bell EJ, Jacobson DJ, Larson NB, Bielinski SJ

Pharmacogenomics and Personalized Medicine 2017, 10:217-227

Published Date: 24 July 2017

Zastrozhin MS, Brodyansky VM, Skryabin VY, Grishina EA, Ivashchenko DV, Ryzhikova KA, Savchenko LM, Kibitov AO, Bryun EA, Sychev DA

Pharmacogenomics and Personalized Medicine 2017, 10:209-215

Published Date: 7 July 2017

Chidambaran V, Zhang X, Martin LJ, Ding L, Weirauch MT, Geisler K, Stubbeman BL, Sadhasivam S, Ji H

Pharmacogenomics and Personalized Medicine 2017, 10:157-168

Published Date: 9 May 2017

Mirzaev KB, Zelenskaya EM, Barbarash OL, Ganyukov VI, Apartsin KA, Saraeva NO, Nikolaev KY, Ryzhikova KA, Lifshits GI, Sychev DA

Pharmacogenomics and Personalized Medicine 2017, 10:107-114

Published Date: 12 April 2017

Original Research

Sychev DA, Shuev GN, Suleymanov SS, Ryzhikova KA, Mirzaev KB, Grishina EA, Snalina NE, Sozaeva ZA, Grabuzdov AM, Matsneva IA

Pharmacogenomics and Personalized Medicine 2017, 10:93-99

Published Date: 31 March 2017

Review

Prince AER, Cadigan RJ, Henderson GE, Evans JP, Adams M, Coker-Schwimmer E, Penn DC, Van Riper M, Corbie-Smith G, Jonas DE

Pharmacogenomics and Personalized Medicine 2017, 10:49-60

Published Date: 20 February 2017

Original Research

Takahashi PY, Ryu E, Pathak J, Jenkins GD, Batzler A, Hathcock MA, Black JL, Olson JE, Cerhan JR, Bielinski SJ

Pharmacogenomics and Personalized Medicine 2017, 10:39-47

Published Date: 14 February 2017

Original Research

Frick A, Fedoriw Y, Richards K, Damania B, Parks B, Suzuki O, Benton CS, Chan E, Thomas RS, Wiltshire T

Pharmacogenomics and Personalized Medicine 2015, 8:81-98

Published Date: 26 February 2015

Original Research

Penney RB, Lundgreen A, Yao-Borengasser A, Edavana VK, Williams S, Dhakal I, Wolff RK, Kadlubar S, Slattery ML

Pharmacogenomics and Personalized Medicine 2014, 7:163-171

Published Date: 14 July 2014

Review

Sechler M, Cizmic AD, Avasarala S, Van Scoyk M, Brzezinski C, Kelley N, Bikkavilli RK, Winn RA

Pharmacogenomics and Personalized Medicine 2013, 6:25-36

Published Date: 4 April 2013

Here is the original post:
Pharmacogenomics and Personalized Medicine - Dove Press

Dennis M. Lox, M.D. Knee Stem Cell Treatments have been seen Across The Nation.

Dennis M Lox, M.D. is an expert in Knee Stem Cell Injections for those who seek an alternative to the unnecessary complex knee surgery of that in the past by providing Knee Stem Cell Treatment. Dennis M. Lox, M.D. has privately owned Medical Centers that do not partake in the fast chain franchise that other Stem Cell Centers are stuck doing, thus he is able provide a more personalized treatment for your particular injury.

Dennis M. Lox, M.D. centers have a professional, caring environment for patients looking for comfort in their time of need and provids follow-ups on your wellbeing to enhance your recovery. Dennis M. Lox, M.D. has been helping patients since 1990 nationally and internationally and has been the focus of the Stem Cell News Worldwide with his expertise and he continually researches new technologies to further Stem Cell advancements.

PUBLICATIONS:

Lox, D.M., Heine, M.W., and Lox, C.D., Hemostatic Alterations Resulting from Chronic Ethanol Ingestion during Tetracycline Therapy in the Rat, Neurobeh, Toxiocol: Vol. 7, 1985.

Lox, C.D. and Lox, D.M., Effects of Acute Ethanol Intoxication Combined with Secobarbitol Abuse on Homeostasis, General Pharm Vol. 16, 1985. 252-258.

PRESENTATIONS:

Lox, D.M., Sports Medicine and Stem Cells: A Clinical Transformation Presentation at the Select Biosciences Conference: Tissue Engineering and Bio printing, Boston, Massachusetts, February 2015

Lox, D.M., Clinical Regulation of Cytokine and Inflammatory Pathways with Autologous Stem Cell Therapy Presentation at the 17th Clinical Applications for Age Management Medicine Group, The Bellagio Hotel, Las Vegas, Nevada, October 2014

Lox, D.M., Moderator 3rd Annual International Conference on Tissue Science and Regeneration, Valencia, Spain, September 2014

Lox, D.M., Athletes and Avascular Necrosis Presentation at the 3rd Annual International Conference on Tissue Science and Regeneration, Valencia, Spain, September 2014Lox, D.M., Managing Sports and Arthritic Complaints with Stem Cells, Presentation at the Select Biosciences Clinical Translation of Stem Cells, Palm Desert, California, April 2014

Lox, D.M., A Professional Football Player with Failed Knee Surgery: A Case of Treatment with Adipose Derived Stem Cells, Presentation at the Tissue Engineering and Regenerative Medicine International Society Asia Chapter (Termis AP) Annual Conference, Shanghai, China, Oct. 2013

Lox, D.M., Chronic Foot Pain in a Ballerina: Treatment with Regenerative Medicine Presentation at the Tissue Engineering and Regenerative Medicine International Society Asia Pacific Chapter (Termis AP) Annual Conference, Shanghai, China, October 2013

Lox, D.M., Knee Osteoarthritis: Quality of Life (Q o L) Measures Following Autologous Stem Cell Therapy Presentation at the International Cartilage Repair Society Annual Meeting, Izmir, Turkey, September 2013

Lox, D.M., Cytokine Modulation with Nutraceuticals as a Synergistic Mechanism for Regenerative Grafting in Osteoarthritis Repair Presentation at the Tissue Engineering and Regenerative Medicine International Society Meeting, Istanbul, Turkey, June 2013

Lox, D.M., Arthritis: Quality of Life (Q o L) Measures following Mesenchymal Stem Cell Therapy Presentation at the Tissue Engineering and Regenerative Medicine International Society Meeting, Istanbul, Turkey, June 2013

Lox, D.M., Can Healthcare Outcomes Be Quantified with Stem Cell Therapy in Osteoarthritis?

Presentation at the World Stem Cell Summit, West Palm Beach, Fl. December 2012

Lox, D.M., Regenerative Rehabilitation of an Elite Soccer Player, Presentation at the First Annual Symposium on Regenerative Rehabilitation, Pittsburgh, PA, November 3-4, 2011.

Lox, D.M., Regenerative Medicine and Tissue Engineering: Ethical Concerns with Health Care Reform, Presentation at the 2011 World Stem Cell Summit, Pasadena, CA on October 2011.

Lox, D.M., Autologous Adipose-Derived Stem Cells in the Rehabilitation of a Soccer Player, Presentation at the Stem Cells Europe 2011 Conference, Edinburgh, Scotland on July 2011.

Lox, D.M., Autologous Human Adipose-Derived Mesenchymal Stem Cells in Orthopedic Medicine: A Veterinary Correlate, Presentation at the 2nd North American Veterinary Regenerative Medicine Conference, Lexington, Kentucky on June 2011.

Lox, D.M., Regenerative Medicine Techniques in Musculoskeletal Medicine, Presented at the

11th Annual Conference of the International Neural Transplantation and Repair, Sand Key, FL on May 2011.

Lox, D.M., Current Regenerative Medicine Techniques, Tampa, Florida on July 10, 2010.

Lox, D.M., Complex Regional Pain Syndrome Course Presentation, American Academy of Physical Medicine and Rehabilitation Annual Assembly (Moderator: Dennis M. Lox, M.D. Speakers: Jose Ochoa, M.D., Gabor Racz, M.D., Dennis M. Lox, M.D.); Seattle, Washington on November 5, 1998.

Lox, D.M., New Treatments in Myofascial Pain and Fibromyalgia, Presented at the Morton Plant/Mease Health Education Center Countryside, Florida on December 13, 2001.

Lox, D.M., Acute Spinal and Pain Syndromes Presented to the Pinellas County Primary Care and OB/GYN physicians, sponsored by Knoll Pharmaceuticals, 1998.

Lox, D.M., Complex Musculoskeletal Assessment and Treatment, Presented to the Zenith Insurance Company; Sarasota, Florida on September 28, 1998.

Lox, D.M., Fibromyalgia, Presented to Cigna Health Care Physicians, sponsored by Health South Rehabilitation Corporation; Tampa, Florida on September 19, 1998.

Lox, D.M., Evaluation of the Difficult Pain Patient, Presented to the Pinellas County Orthopedic Journal Club, sponsored by Knoll Pharmaceuticals; Clearwater, Florida on September 8, 1998.

Lox, D.M., Fibromyalgia, Presented to the Travelers Insurance Company, sponsored by Health South Rehabilitation Corporation; Tampa, Florida on August 19, 1998.

Lox, D.M., Complex Pain Management, Presented to the Physicians of Collier County, sponsored by Knoll Pharmaceuticals; Naples, Florida on May 16, 1998.

Lox, D.M., Managing Pain in a Managed Care, Presented to the Pinellas County Podiatric Medical Association Meeting; Clearwater, Florida on April 14, 1998.

Lox, D.M., Complex Regional Pain Syndrome: The Historical Perspective from Bonica and Beyond, Presented at the 7th Annual John J. Bonica Vail Winter Pain Conference, sponsored by the Ohio State University Medical Center, College of Medicine, Department of Anesthesiology; Vail, Colorado on March 1998.

Lox, D.M., Pain Management, Presented to Lee County Physicians, sponsored by Knoll Pharmaceuticals; Ft. Myers, Florida in December 1998.

Lox, D.M., Managing Pain in a Managed Care Environment, Presented to the Pinellas County Physicians, sponsored by Knoll pharmaceuticals; Clearwater, Florida in December 1997.

Lox, D.M., Regional Pain Syndrome Update, Presented at the 74th Annual Meeting of the American Congress of Rehabilitation Medicine Pain ISIG; Boston, Massachusetts in September 1997.

Lox, D.M., Physical Medicine for Women Who Hurt all Over (Physical and Somatization Considerations, and Complex Regional Pain Syndrome Update, Presented at the 9th Annual OB/GYN Summer Symposium, Womens Health Care in the 90s, sponsored by the University of Oklahoma Health Sciences Center College of Medicine, Department of Obstetrics and Gynecology; Jackson Hole, Wyoming in August 1997.

Lox, D.M., Replacing the Terms of Reflex Sympathetic Dystrophy and Sympathetically Maintained Pain-An Uphill Battle, Presented at the 13th Annual Update in Physical Medicine and Rehabilitation, sponsored by the University of Utah School of Medicine, Division of Physical Medicine and Rehabilitation, Park City, Utah, March 1997.

Lox, D.M., Complex Regional Pain Syndrome, Presented to Claim Management, Utilization Management, Case Managers, Adjustors and Supervisors of the Travelers/Aetna Insurance Companies; Orlando, Florida in August 1996.

Lox, D.M., Soft Tissue Injuries/RSD/Fibromyalgia-The Rational or Irrational Approach to Diagnosis and Treatment, Presented to Claim Management, Utilization Management, Case Managers and Supervisors of Travelers Insurance Company; Tampa, Florida, 1996.

Lox, D.M., Overview of the Soft Tissue Injury/RSD/Fibromyalgia-The Rational or Irrational Approach to Diagnosis and Treatment, Presented to the Regional Adjustors and Personnel of Geico Insurance Company; Macon, Georgia in May 1996.

Lox, D.M., Causalgia/RSD/SMP-History and Treatment, Presented during the Re-Employment rules of Florida Workers= Compensation Conference, sponsored by the Southwest Chapter of NARPPS in May 1996 (2 CME credits).

Lox, D.M., RSD-Treatment Options for the 90s, Presented to the Florida Association of Rehabilitation Professionals in the Private Sector (FARPPS) in March 1996 (2 CME credits).

Lox, D.M., Causalgia/RSD/SMP-The 100 Year War, Presented to The Florida Association of Rehabilitation Professionals in the Private Sector in January 1996 (2 CME credits)

Lox, D.M., The Differential Diagnosis of Spinal Injuries, Presented to the Intracorp Rehabilitation Nurses in April 1992 (4 CME credits).

Lox, D.M., A Physiatrist Approach to Industrial Industries, Presented to the Florida Rehabilitation Nurses in May 1991 (4 CME credits).

Lox, D.M., Skiing Injuries: Prevention and Rehabilitation, Presented at the North American Medical and Dental Association Seminar; Vail, Colorado in February 1989.

Lox, D.M., The Failed Back Patient, Presented at the Annual Texas Physical Medicine and Rehabilitation Society Meeting; Austin, Texas in August 1989.

Lox, D.M., Dermatomal Somatosensory Evoked Potentials and Gadolinium-MRI in the Evaluation of Chronic Low Back Pain, Presented at the 50th Annual Session of the American Academy of Physical Medicine and Rehabilitation; San Antonio, Texas in November 1989.

Lox, D.M., The Evaluation and Treatment of Lumbar Spine Disorders, Presented at the University of Texas Health Science Center at San Antonio, Department of Allied Health; San Antonio, Texas in December 1988.

Originally posted here:
Our Doctors - Knee Stem Cells

DUBLIN--(BUSINESS WIRE)--The "Global Personalized Medicine in Oncology Partnering Terms and Agreements 2014 to 2019" report has been added to ResearchAndMarkets.com's offering.

This report provides comprehensive understanding and unprecedented access to the personalized medicine in oncology partnering agreements entered into by the world's leading companies.

The report provides a detailed understanding and analysis of how and why companies enter personalized medicine in oncology partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

Chapters

The initial chapters of this report provide an orientation of Personalized Medicine in Oncology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Personalized Medicine in Oncology dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Personalized Medicine in Oncology deals since 2014. Deals are listed by headline value, signed by big pharma, most active Personalized Medicine in Oncology dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Personalized Medicine in Oncology dealmaking with a brief summary followed by a comprehensive listing of Personalized Medicine in Oncology deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Personalized Medicine in Oncology partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of Personalized Medicine in Oncology partnering deals signed and announced since Jan 2014. The chapter is organized by specific Personalized Medicine in Oncology technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Personalized Medicine in Oncology partnering company A-Z, deal type definitions and Personalized Medicine in Oncology partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Personalized Medicine in Oncology partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Personalized Medicine in Oncology technologies and products.

Report Scope

This report is intended to provide the reader with an in-depth understanding of the personalized medicine in oncology trends and structure of deals entered into by leading companies worldwide.

The report includes:

In this report, the available contracts are listed by:

Each deal title links via Weblink to online deal records of actual personalized medicine in oncology partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

For more information about this report visit https://www.researchandmarkets.com/research/jhhqcn/personalized?w=4

Read more here:
Personalized Medicine in Oncology: Global Partnering Terms ...

While some researchers still claim that embryonic stem cells (ESCs) offer the best hope for treating many debilitating diseases, there is now a great deal of evidence contrary to that theory. Use of stem cells obtained by destroying human embryos is not only unethical but presents many practical obstacles as well.

"Major roadblocks remain before human embryonic stem cells could be transplanted into humans to cure diseases or replace injured body parts, a research pioneer said Thursday night. University of Wisconsin scientist James Thomson said obstacles include learning how to grow the cells into all types of organs and tissue and then making sure cancer and other defects are not introduced during the transplantation. 'I don't want to sound too pessimistic because this is all doable, but it's going to be very hard,' Thomson told the Wisconsin Newspaper Association's annual convention at the Kalahari Resort in this Wisconsin Dells town. 'Ultimately, those transplation therapies should work but it's likely to take a long time.'....Thomson cautioned such breakthroughs are likely decades away."

-Associated Press reporter Ryan J. Foley "Stem cell pioneer warns of roadblocks before cures," San Jose Mercury News Online, posted on Feb. 8, 2007, http://www.mercurynews.com/mld/mercurynews/16656570.htm

***

"Although embryonic stem cells have the broadest differentiation potential, their use for cellular therapeutics is excluded for several reasons: the uncontrollable development of teratomas in a syngeneic transplantation model, imprinting-related developmental abnormalities, and ethical issues."

-Gesine Kgler et al., "A New Human Somatic Stem Cell from Placental Cord Blood with Intrinsic Pluripotent Differentiation Potential," Journal of Experimental Medicine, Vol. 200, No. 2 (July 19, 2004), p. 123.

***

From a major foundation promoting research in pancreatic islet cells and other avenues for curing juvenile diabetes:

"Is the use of embryonic stem cells close to being used to provide a supply of islet cells for transplantation into humans?

"No. The field of embryonic stem cells faces enormous hurtles to overcome before these cells can be used in humans. The two key challenges to overcome are making the stem cells differentiate into specific viable cells consistently, and controlling against unchecked cell division once transplanted. Solid data of stable, functioning islet cells from embryonic stems cells in animals has not been seen."

-"Q & A," Autoimmune Disease Research Foundation, http://www.cureautoimmunity.org/Q%20&%20A.htm, accessed July 2004.

***

"'I think the chance of doing repairs to Alzheimer's brains by putting in stem cells is small,' said stem cell researcher Michael Shelanski, co-director of the Taub Institute for Research on Alzheimer's Disease and the Aging Brain at the Columbia University Medical Center in New York, echoing many other experts. 'I personally think we're going to get other therapies for Alzheimer's a lot sooner.'...

"[G]iven the lack of any serious suggestion that stem cells themselves have practical potential to treat Alzheimer's, the Reagan-inspired tidal wave of enthusiasm stands as an example of how easily a modest line of scientific inquiry can grow in the public mind to mythological proportions.

"It is a distortion that some admit is not being aggressively corrected by scientists.

"'To start with, people need a fairy tale,' said Ronald D.G. McKay, a stem cell researcher at the National Institute of Neurological Disorders and Stroke. 'Maybe that's unfair, but they need a story line that's relatively simple to understand.'"

-Rick Weiss, "Stem Cells an Unlikely Therapy for Alzheimer's," Washington Post, June 10, 2004, p. A3.

***

"ES [embryonic stem] cells and their derivatives carry the same likelihood of immune rejection as a transplanted organ because, like all cells, they carry the surface proteins, or antigens, by which the immune system recognizes invaders. Hundreds of combinations of different types of antigens are possible, meaning that hundreds of thousands of ES cell lines might be needed to establish a bank of cells with immune matches for most potential patients. Creating that many lines could require millions of discarded embryos from IVF clinics."

-R. Lanza and N. Rosenthal, "The Stem Cell Challenge," Scientific American, June 2004, pp. 92-99 at p. 94. [Editor's note: A recent study found that only 11,000 frozen embryos are available for research use from all the fertility clinics in the U.S., and that destroying all these embryos for their stem cells might produce a total of 275 cell lines. See Fertility and Sterility, May 2003, pp. 1063-9 at p. 1068.]

***

"Embryonic stem cells have too many limitations, including immune rejection and the potential to form tumors, to ever achieve acceptance in our lifetime. By that time, umbilical cord blood stem cells will have been shown to be a true 'gift from the gods.'"

-Dr. Roger Markwald, Professor and Chair of Cell Biology and Anatomy at the Medical University of South Carolina, quoted in "CureSource Issues Statement on Umbilical Cord Blood Stem Cells vs. Embryonic Stem Cells," BusinessWire, May 12, 2004, also at http://curesource.net/why.html.

***

"'We're not against stem-cell research of any kind,' said [Tulane University research professor Brian] Butcher. 'But we think there are advantages to using adult stem cells. For example, with embryonic stem cells, a significant number become cancer cells, so the cure could be worse than the disease. And they can be very difficult to grow, while adult stem cells are easy to grow.'"

-Heather Heilman, "Great Transformations," The Tulanian (Spring 2004 issue), at http://www2.tulane.edu/article_news_details.cfm?ArticleID=5155.

***

"There are still many hurdles to clear before embryonic stem cells can be used therapeutically. For example, because undifferentiated embryonic stem cells can form tumors after transplantation in histocompatible animals, it is important to determine an appropriate state of differentiation before transplantation. Differentiation protocols for many cell types have yet to be established. Targeting the differentiated cells to the appropriate organ and the appropriate part of the organ is also a challenge."

-E. Phimister and J. Drazen, "Two Fillips for Human Embryonic Stem Cells," New England Journal of Medicine, Vol. 350 (March 25, 2004), pp. 1351-2 at 1351.

***

Harvard researchers, trying to create human embryonic stem cell lines that are more clinically useful than those now available, find that their new cell lines are already genetically abnormal:

"After prolonged culture, we observed karyotypic changes involving trisomy of chromosome 12..., as well as other changes... These karyotypic abnormalities are accompanied by a proliferative advantage and a noticeable shortening in the population doubling time. Chromosomal abnormalities are commonplace in human embryonal carcinoma cell lines and in mouse embryonic stem-cell lines and have recently been reported in human embryonic stem-cell lines."

-C. Cowan et al., "Derivation of Embryonic Stem-Cell Lines from Human Blastocysts," New England Journal of Medicine, Vol. 350 (March 25, 2004), pp. 1353-6 at 1355.

***

"[Johns Hopkins University] biologist Michael Shamblott said...major scientific hurdles await anybody wishing to offer a treatment, let alone a cure, based on cells culled from embryos.

"Among the major obstacles is the difficulty of getting embryonic stem cells master cells that generate every tissue in the human body to become exactly the type of cell one wants... Scientists...haven't been able to guarantee purity cells, for instance, that are destined to become muscle cells and nothing else...

"Transplanting a mixed population of cells could cause the growth of unwanted tissues. The worst case could see stem cells morphing into teratomas, particularly gruesome tumors that can contain hair, teeth and other body parts.

"Another issue is timing... Stem cells pass through many intermediate stages before they become intermediate cells such as motor neurons or pancreatic or heart cells. Deciding when to transplant remains an open question, and the answer might differ from disease to disease.

"...In tackling Lou Gehrig's disease, [Johns Hopkins neurologist Dr. Jeffrey] Rothstein figured that cells that haven't committed themselves to becoming motor neurons would stand the best chance, once implanted, of reaching out and connecting with the cells that surround them. What he found, however, is that these immature cells didn't develop much once transplanted into lab animals."

-Jonathan Bor, "Stem Cells: A long road ahead," Baltimore Sun, March 8, 2004, p. 12A.

***

"Tony Blau, a stem-cell researcher at the University of Washington, said it is 'extremely laborious' to keep embryonic cells growing, well-nourished and stable in the lab so they don't die or turn into a cell type with less potential. Researchers need to know how to channel the stem cells to create a specific kind of cell, how to test whether they're pure, and how to develop drugs that could serve as a sort of antidote in case infused stem cells started creating something dangerous, such as cancer.

"Big companies, Blau said, want to know that their drugs will be almost completely stable, standard, pure and consistent, because they can behave differently if they aren't. Stem cells never will achieve that kind of standardization, Blau said, because living cells are more complex than chemically synthesized drugs."

-Luke Timmerman, "Stem-cell research still an embryonic business," Seattle Times, Business & Technology section, February 22, 2004, at http://seattletimes.nwsource.com/html/businesstechnology/2001862747_stemcells22.html.

***

"[W]ithin the ESC research community, realism has overtaken early euphoria as scientists realize the difficulty of harnessing ESCs safely and effectively for clinical applications. After earlier papers in 2000 and 2001 identified some possibilities, research continued to highlight the tasks that lie ahead in steering cell differentiation and avoiding side effects, such as immune rejection and tumorigenesis."

-Philip Hunter, "Differentiating Hope from Embryonic Stem Cells," The Scientist, Vol. 17, Issue 34 (December 15, 2003), at http://www.the-scientist.com/yr2003/dec/hot_031215.html.

***

"Long-term culture of mouse ES [embryonic stem] cells can lead to a decrease in pluripotency and the gain of distinct chromosomal abnormalities. Here we show that similar chromosomal changes, which resemble those observed in hEC [human embryonal carcinoma] cells from testicular cancer, can occur in hES [human embryonic stem] cells.... The occurrence and potential detrimental effects of such karyotopic changes will need to be considered in the development of hES cell-based transplantation therapies."

-J. Draper et al., "Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells," Nature Biotechnology, Vol. 22 (2003), pp. 53-4.

***

"James A. Thompson of the University of Wisconsin, Madison, and his colleagues managed to isolate and culture the first human embryonic stem cells in 1997. Five years later, big scientific questions remain. [Harvard embryonic stem cell researcher Doug] Melton and his colleagues, for instance, don't yet know how to instruct the totipotent stem cells to become the specific cells missing in a diabetic person, the pancreatic beta cell.

"'Normally, if you take an embryonic stem cell, it will make all kinds of things, sort of willy-nilly,' says Melton."

-J. Mitchell, "Stem Cells 101," PBS Scientific American Frontiers, May 28, 2002, http://www.pbs.org/saf/1209/features/stemcell.htm.

***

"Unlike stem cells isolated from the embryo, [adult stem cells] do not carry the same risks of cancer or uncontrollable growth after transplant, and they can be isolated from patients requiring treatment, thus avoiding all problems of immune rejection and the need for immune suppressive drugs that carry their own risks.

"...Embryonic stem cells are promoted on grounds that they are developmentally more flexible than adult stem cells. But too much flexibility may not be desirable. Transplant of embryonic cells into the brains of Parkinson's patients turned into an irredeemable nightmare because the cells grew uncontrollably. Embryonic stem cells also show genetic instability and carry considerable risks of cancer... When injected under the skin of certain mice, they grow into teratomas, tumors consisting of a jumble of tissue types, from gut to skin to teeth, and the same happens when injected into the brain."

-Dr. Mae-Wan Ho and Prof. Joe Cummins on behalf of the Institute of Science in Society (ISIS), "Hushing Up Adult Stem Cells," ISIS report, February 11, 2002, at http://www.i-sis.org.uk/HUASC.php.

***

"'I even hear from patients whose fathers have lung cancer,' said Dr. Hogan, a professor at Vanderbilt School of Medicine. 'They have a whole slew of problems they think can be treated. They think stem cells are going to cure their loved ones of everything.'

"If it ever happens, it will not happen soon, scientists say. In fact, although they worked with mouse embryonic stem cells for 20 years and made some progress, researchers have not used these cells to cure a single mouse of a disease...

"Scientists say the theory behind stem cells is correct: the cells, in principle, can become any specialized cell of the body. But between theory and therapy lie a host of research obstacles...the obstacles are so serious that scientists say they foresee years, if not decades, of concerted work on basic science before they can even think of trying to treat a patient."

-Gina Kolata, "A Thick Line Between Theory and Therapy, as Shown with Mice," New York Times, December 18, 2001, p. F3.

***

"Mice cloned from embryonic stem cells may look identical, but many of them actually differ from one another by harboring unique genetic abnormalities, scientists have learned...

"The work also shows for the first time that embryonic stem cells...are surprisingly genetically unstable, at least in mice. If the same is true for human embryonic stem cells, researchers said, then scientists may face unexpected challenges as they try to turn the controversial cells into treatments for various degenerative conditions."

-Rick Weiss, "Clone Study Casts Doubt on Stem Cells," Washington Post, July 6, 2001, p. A1.

***

"ES cells have plenty of limitations... For one, murine ES cells have a disturbing ability to form tumors, and researchers aren't yet sure how to counteract that. And so far reports of pure cell populations derived from either human or mouse ES cells are few and far between fewer than those from adult stem cells."

-Gretchen Vogel, "Can Adult Stem Cells Suffice?", Science, Vol. 292 (June 8, 2001), pp. 1820-1822 at 1822.

***

"Rarely have specific growth factors or culture conditions led to establishment of cultures containing a single cell type.... [T]he possibility arises that transplantation of differentiated human ES cell derivatives into human recipients may result in the formation of ES cell-derived tumors... Irrespective of the persistence of stem cells, the possibility for malignant transformation of the derivatives will also need to be addressed."

-J. S. Odorico et al, "Multilineage differentiation from human embryonic stem cell lines," Stem Cells Vol. 19 (2001), pp. 193-204 at 198 and 200, at http://stemcells.alphamedpress.org/cgi/reprint/19/3/193.pdf.

Originally posted here:
Practical Problems with Embryonic Stem Cells - usccb.org

The mission of the Seed Biotechnology Center (SBC)is to mobilize the research, educational and outreach resources of UC Davis in partnership with the seed and biotechnology industries to facilitate discovery and commercialization of new seed technologies for agricultural and consumer benefit.

A team of researchers including SBC Director of Research, Dr. Allen Van Deynze and Cristobal Heitmann, discover an indigenous variety of corn that can fix nitrogen from the atmosphere, instead of requiring synthetic fertilizers. Cristobal Heitman, Cris, was a beloved member of the UC Davis Plant Sciences Department. Criss energy and enthusiasm were a major catalyst in this research. Read more.

Plant Breeding Academy Addresses Global Food Needs

UC Davis' Department of Plant Sciences shares how PBA is changing the global food supply one scientist at a time.Read article.

A DryCardis the latest technology to improve the shelf-life of seeds. Dr. Kent Bradford, SBCDirector, describes how the amazingDryCard works. Read more.

Comstock Magazine highlighted the value of locating Sakatas Woodland Innovation Center in the Sacramento Valley. The regions fertile soil and ideal climate make it one of the best places in the world for seed production. In addition, its close proximity to UC Davis will allow Sakata to strengthen its already existing ties to the university. Learn more.

Scientists could engineer a spicy tomato. Is it worth it?

Scientists are working on growing a spicy tomato. Dr. Allen Van Deyneze, SBC Director of Research shares his insight on the research. Read article.

Benson Hill Teams Up with The African Orphan Crops Consortium to Combat Malnutrition Through Underutilized Crops

Allen Van Deynze, Director of Research, Seed Biotechnology Center, University of California, Davis and Scientific Director of the African Orphan Crops Consortium highlights effort to accelerate the ability of African scientists to develop better seeds and improve the diets of Africas children. Learn more

See the rest here:
Welcome to the SBC - Seed Biotechnology Center

According to U. S. records, the number of individuals over 100 years of age known as Centenarians is skyrocketing! In the US in 1840 there were 90 centenarians which is 1 for every 189,000 people. Today there are more than 53,000 which is 1 for every 5,800 people. To find out why some people live so long, the world was searched for places where there are an unusually large number of centenarians. Those places became known as Blue Zones based on a National Geographic book that was published a few years ago.

There were four areas of the world known as Blue Zones in the original book with a fifth more recently addedOkinawa, Japan; Ikaris, Greece; Loma Linda, California; Nicoya, Costa Rico; and Sardinia, Italy. Experts cite that an active lifestyle and a healthy diet as the keys to a longer life. In Blue Zones people are passionate about retaining close family ties and staying closely connected to their neighbors and community organizations.

Okinawa has the highest number of centenarians in the world. Two thirds of the people who reach 100 in this country are able to continue living independently at age 97. These people are three times more likely to reach the age of 100 than maost Americans. Additionally, they have very low rates of stroke, cancer, heart disease and diabetes. Researchers are convinced that their diet is the key component to their longevity.

The diet of Okinawan is high in vegetables and fruits, high in plant proteins, includes seafood and is also rich in whole grains. Scientists from the Eat Lancet Commission say this diet closely resembles their planetary health diet which is a diet that works well for human health and also for reducing the environmental impact of the foods we choose.

Some of the most widely consumed foods in Okinawa include green leafy and yellow root vegetables, sweet potatoes, bitter melon, tofu with modest amount of seafood, lean meat, tea and fruit. This diet is low calorie and high carbohydrate with moderate protein consumption, includes nutrient rich food choices and sparse amounts of refined grains sugar, dairy and meat. A typical meal will include a vegetable stir fry, miso soup, a side of seaweed and freshly brewed jasmine tea.

In addition to a healthy diet, Okinawans maintain close social ties and networks with a grounded sense of purpose. These people remain true to their traditional culture which emphasizes lifelong connections with social and emotional support.

Another Blue Zone is Ikaris, Greece. The residents in this part of the world nap regularly in the middle of the day. None of them exhibit symptoms of depression which non nappers do according to a 2011 study. One study of Greek adults showed that napping on a regular basis reduced the risk of heart disease by close to 40%.

These people of Greece follow a Mediterranean diet which includes natural products produced and consumed on the island of Ikaris. Their diet includes fruits, a variety of vegetables, olive oil, fish, honey, red wine, small quantities of coffee and a variety of herbal teas. Their daily calorie consumption is not high. They have minimal drug use, live a relaxed pace without anxiety and stress, are full of optimism and have strong family and social ties. All characteristics that are abundant in all five Blue Zones!

In Loma Linda, California the proportion of people age 85 or more is more than double the rest of this state. 4 in 10 residents of this city (about 9,000 members) are 7th Day Adventists whose members live longer than any other religious group in America. 7th Day Adventists are 10 times more likely to live to 100 than other Americans. The average male lives to 89 while the average female lives to 91. Both are averages of 10 years longer than the American average. This group of people believe in taking care of their bodies which they do through exercise, healthy diet habits and their close ties to their religious community.

They avoid smoking and alcohol while encouraging exercise and a life full of activity. Their diet typically includes nuts, green salads, fruits, legumes, whole grain cereals and polyunsaturated fats. Many are vegetarians and those who are not eat a low meat diet. They avoid foods high in sugar, salt and stay away from refined grains.

The next Blue Zone is Nicoya, Costa Rica which is known as one of the happiest places in the world! In this area of the world a man at the age of 60 is twice more likely of hitting 90 as a man living in America, France or Japan and residents frequently reach the age of 100. Once again, their long lives are attributed to their healthy lifestyle.

Their largest meal of the day is typically in the morning with their smallest meal of the day at night. They eat little or no processed foods and their diet is primarily plant based. They consume large amounts of beans, vegetables, corn and antioxidant rich tropical fruits. The consume meat only a few times a week and smoking is not common. They also drink a lot of mineral rich water which is very high in calcium and magnesium and get very healthy doses of sunshine on a daily basis.

These people also have a very strong belief in God, and their faith routines help them relieve anxiety and stress and bring tranquility and peace to their lives. They engage in physical activity as a normal part of their daily liveswalking, bicycling, cooking, keeping up their houses, gardening and taking care of animals are all parts of their very active lives.

These residents of Coats Rice focus on family by tending to live with or near their families. Children and grandchildren provide strong support, purpose and a sense of belonging to their elders. This helps Nicoyan elders retain their active lifestyle and positive outlook on life!

Sardinia, Italy is the fifth Blue Zone. There are 21 centenarians in a population of 10,000. In the U. S. there only about 4 centenarians in 10,000. Here Sardinia men live longer than any other men on earth.

There is a large number of sheep herding and farming communities where daily physical activity is strong. Many of these residents walk up to 5 miles a day across rugged terrain. They tend to walk daily to the grocery store. Many Sardinians still fish, hunt and harvest their own food. And even though they are culturally isolated, they remain close to friends and family throughout their lives. They like to laugh and drink wine together!

Their diet like the other Blue Zones is comprised of homegrown vegetables and fruits, beans, fish and milk and cheese from grass fed sheep and goats. Goats milk has components that are thought to protect against inflammatory diseases of aging. And they like their wine! They typically drink a glass or two daily of red wine. Cannonau wine which is the wine produced in this area from the grape known as Grenache, has three times the levels of artery scrubbing flavonoids as other wines.

These people laugh with friends. They gather each afternoon in the street to talk and laugh and the men of this region are famous for their sardonic sense of humor. And their strong sense and support of family keeps the young looking after their elders with many believing that putting an older family member in a retirement home would dishonor the family!

For Americans and others, following the habits of the people living in the five Blue Zones may help improve daily health and longevity. Taking notes about diet, daily exercise and activity; close ties to family, friends and community; purpose; and a positive outlook and gratitude on life are key. It is known that all these factors play a role in aging and age related diseases.

Read the original post:
Anti-Aging, Regeneration and Stem Cell Supplements

center for biomedical education

The mission of the Center for Biomedical Education encompasses education in the basic medical and clinical sciences and educational research related to the training of medical doctors. CBE undertakes and fosters conferences, meetings, workshops, and publications by and for medical educators. Activities further the purposes of ICSM by promoting effective training of medical doctors and thereby conferring a benefit to society.

IIHER is a nonprofit research organization with origins dating back to 1991 whose purpose it is to investigate human evolutionary biology using the widest possible purview. IIHER serves as the basis for paleoanthropological research expeditions, primarily to Africa. Active now is the East Libya Neogene Research Project to the late Miocene site of Sahabi and the middle Miocene site of Jabal Zaltan, Libya.

The primary activity of CFSHR is the forensic scientific investigation of primarily skeletonized human remains worldwide, particularly those found in circumstances indicating abuses of human rights, such as mass graves, ethnic cleansing, torture, or genocide. A secondary activity is forensic assistance lent to medical examiners offices and regional law enforcement agencies primarily in Oregon, California, and Washington in solving missing person and homicide cases.

More:
Integrative Centers for Science and Medicine - Home

The procedure lasts about 3040 minutes, using local anesthetic with very little discomfort, and after it is completed you will be able to walk out of the office and drive yourself home.

This is in contrast to prolonged hospital stays with extensive down time and expense associated with various surgical procedures, including total knee replacements. The average cost of a total knee replacement in the U.S. is $40,000, and often associated with mediocre results, especially with regard to functionality.

Stem Cell Prolotherapy offers a much better solution with potentially better results, especially mobility, at a fraction of the cost. There are other treatment modalities sometimes used to lubricate the knee joint, such as Hyaluronate, known by the brand names, Synvisc or Euflexxa.

The problem with these is that they are only a temporary solution, which at best will only last for about six months before the procedure will need to be repeated. This is in stark contrast to the permanent healing and regeneration, which is achieved with the Stem Cell Prolotherapy.

However, Hyaluronate can be used in conjunction with the Stem Cell Prolotherapy so that you can enjoy the benefits of both therapies, if you choose.

Visit link:
Stem Cell Joint Regeneration | Utah Stem Cells

Overview

For people suffering from Type 2 diabetes, stem cell therapy can offer a respite from the symptoms of the disease. Although stem cell therapy cannot cure it, receiving stem cell therapy for diabetes Type 2 from TruStem Cell Therapy has the potential to improve a patients quality of life significantly by reducing symptoms and complications related to Type 2 diabetes, as well as slowing its progression.

For patients receiving stem cell diabetes treatment, it is possible to see improvements in any one or multiple disease-related complications such as stabilization of blood sugar levels, lower blood sugar levels, frequent urination, fatigue, poor wound healing, etc.

TruStem Cell Therapy provides access to diabetes treatment that utilizes a patients stem cells isolated from his or her own fat tissue. There are multiple benefits afforded by the utilization of adipose-derived stem cells, including their ability to differentiate into a broad variety of cell types (neurons, bone, cartilage, muscle, tendon, etc.), they are present at comparatively much higher levels than other stem cell types; possess higher immunomodulatory capacity; and they do not endanger a patients health the way other stem cells might.

There are three steps to the treatment process:

Approximately 150 to 250 ccs of a patients own fat tissue is harvested through a minimally invasive procedure. Generally, this fat tissue is collected from around the patients belly region.

Typically, patients will experience some soreness and bruising lasting roughly a week as a result of the harvesting procedure. Additional complications from stem cell therapy for diabetes have not been observed. Although the FDA has not approved stem cell therapy for diabetes Type 2 as of yet, more than 100 studies and clinical trials have demonstrated the safety and minimal side effect profile of stem cell therapy.

Because every patient responds differently to treatment, it is difficult to predict the timeline of a patients response. It could take weeks to months for stem cell therapy for diabetes Type 2 to provide noticeable results.

Our focus is on safety, efficacy and patient-centric care when providing access to superior stem cell therapy. We utilize only board-certified surgeons, physicians and accredited clinicians to provide care for patients. Our laboratory protocols are developed and refined by our PhD neuroscientist, and our clinical team has extensive expertise in practicing cellular-based medicine. Our accredited surgical centers are geared toward enhanced procedural and patient safety. Above all, TruStem Cell Therapy has skilled patient advocates who are trained to provide truthful, realistic expectations resulting from stem cell therapy. We do not make outlandish promises of cures, or inaccurate claims related to improvement rates.

Type 2 diabetes is a relatively common disorder that causes high blood sugar levels. Though it may sound innocuous, high blood sugar can lead to symptoms like frequent urination, increased thirst and blurred vision; as well as more severe health-related complications, including fatigue, cardiovascular disease, stroke and kidney failure.

Type 2 diabetes develops when the body becomes resistant to or stops producing insulin: a hormone that helps remove sugar from blood and allows it to be absorbed into various tissue types like muscle and fat. Exactly why this happens is unknown, although genetics and environmental factors such as excess weight and inactivity seem to be contributing factors.

Living with Type 2 diabetes can be difficult, but TruStem Cell Therapy may be able to help you live a more comfortable and fulfilling life through stem cell diabetes treatment. If youd like to learn more about how we might be able to help you, contact us today.

Symptoms/Complications

Frequent urination

Increased thirst and hunger

Blurred vision

Fatigue

Cardiovascular disease

Stroke

Blindness

Kidney failure

Lower limb amputations

Causes

Type 2 diabetes develops when the body becomes resistant to insulin or when the pancreas stops producing enough insulin. Exactly why this happens is unknown, although genetics and environmental factors, such as excess weight and inactivity, seem to be contributing factors.

TruStem Cell Therapy

TruStem Cell Therapy provides access to treatment that utilizes a patients stem cells isolated from their own fat tissue. There are multiple inherent benefits afforded by the utilization of adipose derived stem cells including their ability to differentiate into a broad variety of cells types (neurons, bone, cartilage, muscle, tendon, etc.), they are present at comparatively much higher levels than other stem cell types, possess higher immunomodulatory capacity, and they do not endanger a patients health the way other stem cells might.

Approximately 150-250ccs of a patients own fat tissue is harvested through a minimally invasive, mini liposuction procedure. Generally, this fat tissue is collected from around the patients belly region.

Harvested fat tissue is immediately taken to the onsite laboratory for processing. At this step, an optimized protocol is used to isolate the maximum number of stem cells from collected fat tissue.

TruStem Cell Therapy utilizes both systematic and novel administration methods to fully saturate the body with stem cells while targeting specific areas of injury.

DT2 patients who receive stem cell therapy through us can receive multiple systemic and targeted administration methods:

Intravenously ADSCs are delivered via a vein for distribution throughout the body

Direct site injections ADSCs are delivered to sites that need repair, such asIschemic limbs andNeuropathy or nerve damage to various areas of the body.

Our focus is safety, efficacy, and patient-centric care when providing access to superior stem cell therapy.

We utilize only board certified surgeons, physicians and accredited clinicians to provide care for patients.

Laboratory protocols are developed and refined by our PhD Neuroscientist.

A clinical team with expertise in practicing cellular based medicine.

Accredited Surgical Centers for enhanced procedural and patient safety

Targeted administration methods that direct stem cells toward specific

Skilled Patient Advocates who are trained to provide truthful, realistic expectations resulting from stem cell therapy. We do not make outlandish promises of cures or inaccurate claims related to improvement rates.

FAQ

Unfortunately, not at this time. We are only providing access to stem cell therapy for Type 2 Diabetes. To date there is not enough research or clinical evidence to support the use of adult stem cell therapy as an effective therapy option for patients with type 1 diabetes. However, this may change with future advances so please return for updates on this matter.

It is important for patients and caregivers to understand that current therapies, including stem cell treatment, does not provide a cure for type 2 diabetes. However, TruStem Cell Therapy does have the potential to improve a patients quality of life by reducing symptoms and complications related to type 2 diabetes as well as slowing its progression.

The FDA has not approved stem cell therapy for type 2 diabetes. As noted above, studies have demonstrated the safety and efficacy of stem cell therapy for this condition but additional studies are needed before FDA approval can be secured.

It is possible through these treatments, to improve a patients quality of lifebyminimizing disease relatedsymptoms and complications. For Type II Diabetes patients, it is possible to see improvements in any one ormultipledisease related complications such as: stabilization of blood sugar levels, lower blood sugar levels, frequent urination, fatigue, poor wound healing, etc If you have questions regarding how these treatments may help you, please contact one of our Patient Advocates to learn more.

It is difficult to predict the timeline of a patients response. Every patient responds differently to treatment. It could take weeks to months for the stem cells to provide noticeable results.

Typically patients will experience some level of soreness and bruising lasting roughly a week as a result of the mini-liposuction procedure. Additional complications have not been observed. Over a hundred studies and clinical trials have demonstrated the safety and minimal side-effect profile of stem cell therapy.

Read the rest here:
Stem Cell Treatment & Therapy for Diabetes Type 2 in ...

Cardiac-Pulmonary Conditions

Led by Melvin M. Propis, M.D., South Florida Stem Cell Center is one of theleading Stem Cell Regenerative Therapy Clinics in South Florida. Dr. Propis is a seasoned M.D. and surgeon who has had solid success rates.

Stem Cell Regenerative Therapy is a breakthrough in medical science that treats and prevents conditions and diseases using stem cells. This is accomplished by harvesting cells and then concentrating those cells in a lab before precisely re-injecting them. This greatly increases your bodys own natural repair cells and promotes healing.

South Florida Stem Cell Center is made up of research scientists and experts in Stem Cell Therapy.Our passion and belief is that our treatments truly helpthose that are suffering and need our help.

Maribella MKnee Injury

I injured both of my knees. After confirming that the cartilage was still in the joint, Dr. Propis injected my knees with a mixture of stem cells and PRP 4 months ago. Today I walk comfortably, No pain in those joints. I have noticed significant improvement in my balance and no longer need a walker or narcotics for pain.

Mia HCrohn's Disease

I have had Crohns disease for most of my short life which has led me to miss out on many teenage activities. After seeing other patients improve from having stem cells injected, I (and my mother) decided to try it. It was a wonderful thing to gradually be able to discontinue giving myself Humara shots routinely. I can actually have an active social life without worrying and even married the love of my life last year. Thanking my doctor, mom, God, and the many people who believe in stem cells for my happy ending!

George BDiabetes

I flew to the US in hopes of getting help for my diabetes. Having tried medicine & diets with no results, I was ready to try stem cells. After 1 treatment (and a six month period) I am off all meds and not considered diabetic anymore. To me, life changing! Especially after a relatively simple procedure. Thank you to the office of Dr. Propis and staff.

We Specialize In Treating:

Immunological Conditions

A chronic inflammatory bowel disease that affects the lining of the digestive tract.

Widespread muscle pain and tenderness.

A chronic inflammatory disorder affecting many joints, including those in the hands and feet.

An inflammatory disease caused when the immune system attacks its own tissues.

Please reload

Enjoy The World Again. Call Us Now To Schedule A Treatment Or Consultation

Neurological Conditions

A congenital disorder of movement, muscle tone, or posture.

Damage to the brain from interruption of its blood supply.

A progressive disease that destroys memory and other important mental functions.

A disease in which the immune system eats away at the protective covering of nerves.

A disorder of the central nervous system that affects movement, often including tremors.

Please reload

Enjoy The World Again. Call Us Now To Schedule A Treatment Or Consultation

Degenerative Conditions

Damage to any part of the spinal cord or nerves at the end of the spinal canal.

A chronic condition that affects the way the body processes blood sugar (glucose).

Kidney Failure (Renal Failure)

A condition in which the kidneys lose the ability to remove waste and balance fluids.

A type of arthritis that occurs when flexible tissue at the ends of bones wears down.

Occurs when a man can't get or keep an erection firm enough for sexual intercourse.

Please reload

Enjoy The World Again. Call Us Now To Schedule A Treatment Or Consultation

Read the rest here:
South Florida Stem Cell Center | Regenerative Therapy Clinic

The fertilised egg is the only (totipotent) stem cell that can give rise to a human being. Cells found in the early embryo (the blastomeres and the inner cell mass of the blastocyst) can give rise to pluripotent embryonic stem cell cultures that maintain the ability to mature into all the different cell types found in the fully developed body.

Stem cells in the adult body (adult stem cells or tissue-specific stem cells) are used by the body to replace old and damaged cells. As opposed to pluripotent stem cells, adult stem cells can normally only mature into a limited number of specialised cell types (multipotent). Therefore, Novo Nordisk focuses on pluripotent stem cells as a basis for cell therapy.

Research on adult stem cells has been taking place for more than 30 years, and has not been subject to ethical objections, whereas research on stem cells obtained from surplus embryos donated with freely given informed consent is a central issue in the ongoing ethical debate, because the embryo is lost in the process of establishing one continuous cell line. However, new scientific findings show that a human embryonic stem cell line can be established from one single cell of the blastomere stage without affecting the vitality of the embryo. This technique can also be used to generate human embryonic stem cell lines from non-viable blastocysts (which are discarded anyway by IVF clinics).

Currently, the best defined and most extensively used stem cell treatments are based on adult stem cells, including blood stem cell transplantation to treat diseases and conditions of the blood and immune system. Pluripotent stem cells themselves cannot directly be used for therapies as in their undifferentiated state. They will first need to be coaxed into specialised cell types before transplantation. Therefore, it is critical that these cells are proven safe and efficacious in preclinical and controlled clinical trials. Many potential stem cell-based treatments are currently being tested in animal models and a few have been brought to clinical trials, with the first phase 1/2 clinical trial approved by the US Food and Drug Administration (FDA) in 2010.

Read the original post:
Stem cell research - novonordisk.com

Gene therapy has been studied for more than 40 years and can help stop or slow the effects of disease on the most basic level of the human bodyour genes. And to understand how it works, well start at the basics.

Genes are made up of DNA, which are blueprints to build enzymes and proteins that make our body work. As far as we know, humans have between 20,000 and 25,000 genes. We typically get two copies of each gene from our parents. They influence everything from the color of our hair to our immune system, but genes arent always built correctly. A small adjustment to them can change how our proteins work, which then alter the way we breathe, walk or even digest food. Genes can change as they go through inherited mutations, as they age, or by being altered or damaged by chemicals and radiation.

In the case that a gene changesalso known as mutatingin a way that causes disease, gene therapy may be able to help. Gene therapy is the introduction, removal or change in genetic materialspecifically DNA or RNAinto the cells of a patient to treat a specific disease. The transferred genetic material changes how a proteinor group of proteinsis produced by the cell.

This new genetic material or working gene is delivered into the cell by using a vector. Typically, viruses are used as vectors because they have evolved to be very good at sneaking into and infecting cells. But in this case, their motive is to insert the new genes into the cell. Some types of viruses being used are typically not known to cause disease and other times the viral genes known to cause disease are removed. Regardless of the type, all viral vectors are tested many times for safety prior to being used. The vector can either be delivered outside the body (ex-vivo treatment) or the vectors can be injected into the body (in-vivo treatment).

Other types of drugs are typically used to manage disease or infection symptoms to relieve pain, while gene therapy targets the cause of the disease. It is not provided in the form of a pill, inhalation or surgery, it is provided through an injection or IV.

What Counts as a Rare Disease?

Gene therapy treats diseases in patients that are rare and often life threatening. Rare is defined as any disease or disorder affecting fewer than 200,000 people in the U.S. by the National Institutes of Health. As of now, there are around 7,000 rare diseases, affecting a total of approximately one in ten people. Many of these rare diseases are caused by a simple genetic mutation inherited from one or both parents.

Show Answer

Which Diseases Have Gene Therapies?

Of gene therapies up for approval over the next five years, 45 percent are anticipated to focus on cancer treatments and 38 percent are expected to treat rare inherited genetic disorders. Gene therapy can help add to or change non-functioning genescreating a great opportunity to assist with rare inherited disorders, which are passed along from parents. The mutation might be present on one or both chromosomes passed along to the children. The majority of gene therapies are currently being studied in clinical trials.

Some of these inherited diseases include (but are not limited to):

Show Answer

Why Do We Use Viral Vectors?

As you know from cold and flu season, viruses are quite skilled in the art of invading our bodiesadding their genetic material into our cells. However, researchers have learned to harness this sneaky ability to our advantage. Viruses are often used as a vehicle to deliver good genes into our cells, as opposed to the ones that cause disease.

Viruses are sometimes modified into vectors as researchers remove disease-causing material and add the correct genetic material. In gene therapy, researchers often use adeno-associated viruses (AAV) as vectors. AAV is a small virus that isnt typically known to cause disease in the first place, significantly reducing a chance of a negative reaction.

Show Answer

Read more from the original source:
Gene Therapy Basics | Education | ASGCT American Society ...

The Department of Molecular Genetics is administered from the Medical Sciences Building and has nearly 100 faculty members whose labs are located within the Medical Science Building, the Best Institute, the Donnelly Centre for Cellular and Biomolecular Research, the FitzGerald Building, the Hospital for Sick Children, Mount Sinai Hospital, the Ontario Institute for Cancer Research, and Princess Margaret Hospital.

The Master of Science and Doctor of Philosophy programs in Molecular Genetics offer research training in a broad range of genetic systems from bacteria and viruses to humans. Research projects include DNA repair, recombination and segregation, transcription, RNA splicing and catalysis, regulation of gene expression, signal transduction, interactions of host cells with bacteria and viruses, developmental genetics of simple organisms (worms and fruit flies) as well as complex organisms (mice), molecular neurobiology, molecular immunology, cancer biology and virology, structural biology, and human genetics and gene therapy.

Students may also be interested in the combined degree program inMedicine, Doctor of / Doctor of Philosophy (MD/PhD).

See video Explore Graduate Programs at the Faculty of Medicine

Molecular GeneticsMSc, MD/PhD, Ph

See the article here:
Molecular Genetics - University of Toronto

Gene therapy is designed to introduce genetic material into cells to compensate for abnormal genes or to make a beneficial protein. If a mutated gene causes a necessary protein to be faulty or missing, gene therapy may be able to introduce a normal copy of the gene to restore the function of the protein.

A gene that is inserted directly into a cell usually does not function. Instead, a carrier called a vector is genetically engineered to deliver the gene. Certain viruses are often used as vectors because they can deliver the new gene by infecting the cell. The viruses are modified so they can't cause disease when used in people. Some types of virus, such as retroviruses, integrate their genetic material (including the new gene) into a chromosome in the human cell. Other viruses, such as adenoviruses, introduce their DNA into the nucleus of the cell, but the DNA is not integrated into a chromosome.

The vector can be injected or given intravenously (by IV) directly into a specific tissue in the body, where it is taken up by individual cells. Alternately, a sample of the patient's cells can be removed and exposed to the vector in a laboratory setting. The cells containing the vector are then returned to the patient. If the treatment is successful, the new gene delivered by the vector will make a functioning protein.

Researchers must overcome many technical challenges before gene therapy will be a practical approach to treating disease. For example, scientists must find better ways to deliver genes and target them to particular cells. They must also ensure that new genes are precisely controlled by the body.

Go here to see the original:
How does gene therapy work? - Genetics Home Reference - NIH

Regeneration is, of course, the Holy Grail of medicine. Many diseases are chronic because they are a consequence of damage to organs or tissues beyond any natural repair mechanism. When kidneys are damaged beyond repair, the only answer may be transplantation (severely restricted due to the scarcity of donors) or dialysis a terrible burden on patients (over 350,000 in the U.S.) who are forever tethered to their condition by weekly and sometimes daily visits to a machine. Harnessing the power of the kidneys innate ability to regenerate could enable patients to regain their health.

The kidney actually ranks very highly in its ability to repair itself, said Joseph Bonventre, MD, PhD Professor of Medicine at Harvard Medical School, Chief of the Renal Division at Brigham and Womens Hospital, and head of the HSCI Kidney Disease Program.

Bonventre and his team study the mechanisms by which the kidney repairs tissue after disease, particularly the repair of nephrons, which are the key functional units of the kidney. The nephron consists of a filtering unit for the blood, the glomerulus, and a complex tubule responsible for filtering the blood. The small tubules collect the filtrate and process it before passing it on to ducts leading to the bladder. If tubules are damaged they can be repaired but if the damage is severe enough the nephron may be destroyed. Unfortunately the kidney can regenerate and recover, but the kidney cannot make new nephrons, and in that context, its regeneration is limited.

What happens to the tubules is a clinically relevant question. In kidney disease, whether the disease starts in the filters or the tubules, the tubules ultimately become involved as they are highly susceptible to injury. A reduction in blood flow can lead to a restriction in the supply of oxygen, which can be lethal to the epithelial cells that form the lining of the tubules. For acute kidney injury, the tubules are often (but not always) capable of recovering completely. In chronic kidney failure, the injuries are progressive and nephrons are lost.

Many theories exist on kidney repair. Some suggest that the kidney may recruit circulating stem cells to migrate into and regenerate the damaged area, others that local tissue specific stem cells may be triggered to differentiate and rebuild, and still others that the kidney may forego a direct role for stem cells altogether by inducing mature cells to proliferate.However, a recent study by Bonventre, HSCI Affiliated Faculty member Benjamin Humphreys, MD, PhD, HSCI Executive Committee Member Andrew McMahon, PhD, and their team went a long way toward understanding how the tubules repair themselves.

By tagging the mature epithelial cells that form the tubule walls with a red fluorescent protein, the HSCI team was able to demonstrate that the replacement cells after injury are coming from the epithelium itself rather than from circulating stem cells that enter the kidney or local tissue specific stem cells in the tissue between the tubules. These stem cells might not be sitting on the sidelines, however. Other evidence suggests that they may be offering some assistance in causing the epithelial cells to multiply.

The Harvard Stem Cell Institute basically has allowed us to look at kidney disease in a different and, in many cases, quite definitive way. Joseph Bonventre, MD, PhD

In over 35 years of studying the repair of damaged kidneys, Bonventre suggests that the field may be reaching an inflection point. The Harvard Stem Cell Institute basically has allowed us to look at kidney disease in a different and, in many cases, quite definitive way, said Bonventre. Were understanding the processes much better so that we can now focus on the cell biology related to the intrinsic capacity for the kidney to renew itself.

Collaboration among HSCI researchers has been key to advancing this understanding by sharing expertise as well as findings from model organisms such as the mouse and the zebrafish. Andy McMahon is a world class investigator who has made enormous contributions to the understanding of the way the kidney matures during development, said Bonventre. It has been very productive to apply this knowledge to understanding repair in the adult organ. The team is also using knowledge of the kidneys ability to renew itself to find out how to protect it from further damage. We have found in mice that we can precondition the kidney to be protected against a subsequent injury simply by temporarily cutting off blood flow to parts of the organ and coming back one to two weeks later and finding that when we cut off blood supply again the kidney is not damaged, said Bonventre. We want to understand what causes the protection against the second injury. Is there a cell that goes into the kidney, or some other factor involved? If these protective factors can be found, they could potentially be developed as drugs or treatments that prevent kidney damage in highrisk individuals.

Another use of kidney cells grown in the laboratory is in screens for the potential toxicity of drugs before they are introduced into animals or humans. There really is no good model for in vitro kidney toxicity screening today, because the cells tend to lose their differentiated state and become less kidney-like or less epithelial-like outside the body. Bonventre and colleagues are working on ways to control cell behavior and maintain their state to make better predictive screens. We will be working with Lee Rubins group at the HSCI Therapeutic Screening Center to help us screen for molecules that will keep cells differentiated in culture. If we can do that, we can use them for toxicology and for more sophisticated kidney assist devices, said Bonventre.

Taking that technology back inside the body, one might even use the differentiated cells to create artificial tubules and nephrons with the help of bioengineered materials - completing the regeneration that the kidney is unable to do on its own.

Patients might not have to wait too long to see the benefits of this research. Based on animal studies that suggested an indirect role for stem cells in kidney repair, clinical trials aimed at preventing or rolling back kidney damage in cardiac patients have already begun.

Excerpt from:
The kidney repair shop | Harvard Stem Cell Institute (HSCI)

What is Personalized Medicine?

Genes are part of our DNA, or genetic blueprint. Personalized medicine is a way to gather information about the unique genetic makeup of your brain tumor that can help you and your physician decide on the best treatment plan for you.

Personalized medicine makes a more targeted approach to treatment possible. It provides data about sensitivities or resistance your tumor may have. It can determine how likely you are to respond to certain medicines, steering your doctor toward the safest, most effective choice whether an FDA-approved drug or one only available in a leading-edge clinical trial.

Personalized medicine is a simple, painless process. It involves taking only a small amount of tissue through a biopsy, which is sent for an analysis of the hundreds of known cancer genes. The results are available in two to three weeks. Your Cleveland Clinic physician will call you to discuss the findings and what they mean for your course of treatment.

Personalized medicine is extremely sensitive in finding all types of changes in genes, with no false positives. More than two-thirds of the changes it detects would not be able to be found by any other kind of testing. However, there is no guarantee that the testing will generate results that will be useful in guiding your therapy.

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Continued here:
Personalized Medicine for Brain Tumors | Cleveland Clinic

Our health is determined by many factors, among them: the genetics we inherit; our race, age and gender; our lifestyle; and our socioeconomic environment. These factors differ for everyone and change over our lifespan. Also unique to everyone is their experience with disease and how they respond to prescription drugs or other medical therapies.

Personalized medicine is the use of genomic information in addition to family history, lifestyle, and environmental factors to customize health management. By combining genomic and clinical information, more accurate predictions can be made about a person's susceptibility of developing disease, the course of disease, and response to treatment.

When your genetic information informs your increased risk for a disease and you make lifestyle changes to reduce that risk, personalized medicine has revealed itself. If you have a gene variation that influences how you process a medication and your physician prescribes dosing instructions accordingly, your medical care is now safer, well-timed, accurate, and more cost-effective for you and our healthcare system.

Personalized medicine has the potential to offer patients and their doctors several advantages, including:

Personalized medicine is a relatively new field, and outcomes research and evidence-based literature is important to its integration into healthcare delivery. The Coriell Personalized Medicine Collaborative(CPMC) research study is contributing to both: CPMCstudy participants regularly complete follow-up questionnaires that explore how they are using the information they receive from the study, whether they are making lifestyle changes to reduce their disease risk or improving their medication response, and if they are sharing their results with family and healthcare providers. Additionally, Coriell has and will continue to publish scientific findings from the CPMCstudy, contributing to new medical literature.

Here on the Coriell research study website you will learn more about the utility of personalized medicine in clinical care, how physicians can prescribe medications that will be more efficient for you, and how the CPMCstudy is reporting many health conditions and drug responses to study participants.

For more information about personalized medicine, visit the follow sites:

The human body is composed of trillions of cells cells being the building blocks of all living things. [ Learn More ]

Pharmacogenomics is the study of genetic variation and medication response. [ Learn More ]

Learn how genetic information can be used in clinical decision-making and preventive care. [ Learn More ]

Continue reading here:
Personalized Medicine - Coriell Personalized Medicine ...

There is a lot of overlap between the terms "precision medicine" and "personalized medicine." According to the National Research Council, "personalized medicine" is an older term with a meaning similar to "precision medicine." However, there was concern that the word "personalized" could be misinterpreted to imply that treatments and preventions are being developed uniquely for each individual; in precision medicine, the focus is on identifying which approaches will be effective for which patients based on genetic, environmental, and lifestyle factors. The Council therefore preferred the term "precision medicine" to "personalized medicine." However, some people still use the two terms interchangeably.

Pharmacogenomics is a part of precision medicine. Pharmacogenomics is the study of how genes affect a persons response to particular drugs. This relatively new field combines pharmacology (the science of drugs) and genomics (the study of genes and their functions) to develop effective, safe medications and doses that are tailored to variations in a persons genes.

Read the rest here:
What is the difference between precision medicine and ...